OncoMatch/Clinical Trials/NCT06607627
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Is NCT06607627 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Gefurulimab for generalized myasthenia gravis.
Treatment: Gefurulimab — The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Required: Stage MGFA CLASS II, MGFA CLASS III, MGFA CLASS IV (MGFA)
Diagnosis of MG with generalized muscle weakness meeting the clinical criteria defined by Myasthenia Gravis Foundation of America (MGFA) Class II, III or IV
Demographics
Prior therapy
Cannot have received: thymectomy or any other thymic surgery
Exception: allowed if >12 months prior to Screening
History of thymectomy, or any other thymic surgery within 12 months prior to Screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Washington D.C., District of Columbia
- Research Site · Norfolk, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06607627 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior thymectomy or any other thymic surgery disqualifies patients from enrollment.
What disease stage is eligible?
Stage MGFA CLASS II or MGFA CLASS III or MGFA CLASS IV is required.
Is there an age limit?
Yes. Patients must be 17 years or younger and at least 6 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify